TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06679075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy using sodium hypochlorite and bioceramic putty
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and bioceramic putty as a dressing material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full pulpotomy using sodium hypochlorite and MTA
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and MTA as a dressing material.
Study: NCT06680284

Intervention type: OTHER
Intervention: Staff Education Program
Description: A staff education and environmental awareness campaign and in-service to highlight strategies to reduce, reuse, and recycle waste, as well as proper waste disposal practice, will be implemented by way of instructional posters, e-learning modules, a grand rounds presentation, journal club discussion, and brainstorming sessions for waste reduction, reuse and recycle and a brief knowledge test at the end.
Study: NCT06680297

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrates loading
Description: Patient who is randomised in the intervention group will receive Nestle drink 2hours before the operation and a night before operation. They will receive 10mls/kg a night before operation and 5mls/kg 2 hour before operation of the carbohydrate drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patient assigned to this group will receive standard surgical fasting treatment which include 6hrs of fasting and 2 hrs of clear fluid prior operation
Study: NCT06680557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercises
Description: * Aerobic exercise session: A 30-minutes of brisk walking exercise on an indoor track without speed walking or running .~* Resistant exercise session: A 30-minutes of resistance exercise using rubber bands including warm-up and cool-down periods. Rubber band exercises are composed of seven exercises: squat, leg extension, pull apart, seated row, standing biceps curl, overhead press and lateral raise. Each exercise consists of three sets of 10 repetitions with 1 minute rest between each exercise set.
Study: NCT06681636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus 9-valent vaccine, Recombinant
Description: HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human papillomavirus 9-valent vaccine, Recombinant
Description: HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human papillomavirus 9-valent vaccine, Recombinant
Description: HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58
Study: NCT04180722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aTouchAway™ platform
Description: Participants will receive multi-component Virtual Transition Intervention. The four components of the intervention comprise: (1) routine virtual clinic visits scheduled at the same frequency as usual care; (2) virtual care plan and action plan for respiratory infection/deterioration and management of ventilator issues; (3) remote, weekly and monthly monitoring of ventilator and cough assist metrics, VAI symptoms, and oxygen saturations; and (4) as needed clinical consultations triggered by identification of abnormal parameters or requested by the VAI or family caregiver.
Study: NCT05136690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine 21 mg transdermal nicotine patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine 21 mg transdermal nicotine patch.
Study: NCT05669027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham (Placebo Control)
Description: Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
Study: NCT05136690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4334
Description: MK-4334 250 mg capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4334
Description: MK-4334 250 mg capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule taken by mouth.
Study: NCT06588738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: ESK-001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Apremilast
Study: NCT06680856

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+HA
Description: treatment of diabetic foot ulcers with allogeneic PRP+HA

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: treatment of diabetic foot ulcers with HA
Study: NCT06680193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing of Positive Memories Technique
Description: PPMT was administered weekly as a 4-session protocol. In session 1, participants receive psychoeducation on PTSD symptoms, an overview of PPMT, and are assessed for psychological symptoms. Sessions 1-4 involve the detailed processing of a salient positive autobiographical memory to elicit values, affect, strengths, and thoughts related to that positive memory. Homework assignments include listening to an audio recording of that memory, completing a values, affect, strengths, and thoughts log, and engaging in a behavioral activity. In session 4, the therapist also reviews psychological symptoms and addresses termination.
Study: NCT06678620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reinovax PCV24 formulation 1
Description: One dose of Reinovax PCV24 formulation 1（0.5mL）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reinovax PCV24 formulation 2
Description: One dose of Reinovax PCV24 formulation 1（0.5mL）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reinovax PCV24 formulation 3
Description: One dose of Reinovax PCV24 formulation 1（0.5mL）

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
Study: NCT05830084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib tablet
Description: Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)
Study: NCT06679829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: 11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2
Study: NCT06624358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Physical Activity
Description: Behavioral interventions to improve physical activity
Study: NCT05065528

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
Study: NCT06626958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Stress Ball app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Stress Ball app
Study: NCT06685068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN1286
Description: Specified dose on specified days
Study: NCT06686238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MITOVIT® Hypoxic Training System
Description: The EG (Experimental Group) will undergo a single session of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MITOVIT® Hypoxic Training System
Description: The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
Study: NCT06099821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. It has been also reported to have anti-tumor efficacy in other kinds of digestive system cancers.
Study: NCT04750629

Intervention type: DEVICE
Intervention: POC CoviDx™ Rapid Antigen Test
Description: All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
Study: NCT05492474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Point of Care Ultrasound
Description: Cranial ultrasound involves 2-dimensional B mode imaging of the brain parenchyma in the axial plane using a 1-2 MHz probe through the thin temporal bone. Upload of cPOCUS images will occur over DICOM® based Health Insurance Portability and Accountability Act (HIPAA) compliant platforms accessible via Cloud. Currently all handheld machines use Tricefy® or their own cloud based remote image access application.
Study: NCT06510283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taitacept
Description: Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
Study: NCT06631755

Intervention type: DEVICE
Group type: OTHER
Intervention: Xience Skypoint stent over calcified coronary lesions
Description: Patients with Xience Skypoint stent implanted after OCT assesment of calcification
Study: NCT06704776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The medially pedicled IPFP flap group
Description: In the The medially pedicled IPFP flap group, the IPFP was exposed and separated, and the lateral side was left intact and the medial side was tipped to form a complete medially tipped IPFP flap, and the IPFP flap was clipped and draped over the medial side to avoid interference of the IPFP with the operative field. After successful implantation of the prosthesis, the IPFP was fixed with in situ sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete IPFP removal group
Description: The entire IPFP was resected from below the patellar tendon prior to femoral preparation.
Study: NCT06708702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copaíba mouthwash
Description: A 15% aqueous solution of copaíba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula of copaíba oil (Copaifera Officinalis Resin) 15%, liquid mint aroma 5%, tween 80 1%, aqueous solution (Distilled water + Nipagin 0.1%) qsp 100%.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use.
Study: NCT06673264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Neural Probe
Description: sub-acute insertion of the soft neural probe with neural signal recording
Study: NCT06674902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Description: EPTE device (Ionclinics, Valencia, Spain)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Description: EPTE device (Ionclinics, Valencia, Spain)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Description: EPTE device (Ionclinics, Valencia, Spain)
Study: NCT06708702

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Placebo will be used, under the formula of liquid mint flavor 5%, Nipagim 0.1%, and distilled water qsp 60 ml, packed in packaging compatible with that of the product under investigation, maintaining the same physical characteristics to maintain blinding. The product will be stored at room temperature and stored in the INCA pharmacy.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use.
Study: NCT06709118

Intervention type: DEVICE
Intervention: fiberoptic
Description: Tracheal intubation was performed with different outer diameters of fiberoptic.

Intervention type: DEVICE
Intervention: fiberoptic
Description: Tracheal intubation was performed with different outer diameters of fiberoptic.
Study: NCT05805345

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A toric soft contact lens
Description: Commercially available silicone hydrogel contact lens
Study: NCT06467955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet System, DI Biofragmentable
Description: Anastomoses achieved by magnetic compression.
Study: NCT06271356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BC-Navigate
Description: BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
Study: NCT06122415

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Amyloid Probability Score 2 (APS 2) score
Description: APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma ptau217/nptau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study: NCT06709118

Intervention type: DEVICE
Intervention: fiberoptic
Description: Tracheal intubation was performed with different outer diameters of fiberoptic.
Study: NCT06710379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRX-0405
Description: Antibody Drug Conjugate targeting STEAP1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRX-0405
Description: Antibody Drug Conjugate targeting STEAP1
Study: NCT06709768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS)
Description: This is a pilot test of the MAPSS-MS intervention in a virtual delivery format.
Study: NCT06122415

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma ptau217
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma neurofilament light (NfL)
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study: NCT06708780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded Human Autologous Regulatory T Cells
Description: Peripheral blood component donation is used to collect Treg cells for ex vivo expansion, with technical guidance provided by the Center for Biotechnology Drug Development at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: Routine care is provided to all participants according to clinical guidelines for T1DM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Routine care is provided to all participants according to clinical guidelines for T1DM.